AXLA
Axcella Health Inc
Employees
58
Industry
Research and Development in Biotechnology
axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
4.58
P/E Ratio
-0.25
52-wk high
4.58
Low
4.58
Div yield
N/A
52-wk low
4.58

Portfolio Pulse from Benzinga Newsdesk
September 28, 2023 | 2:28 pm
Portfolio Pulse from Benzinga Newsdesk
September 28, 2023 | 2:22 pm
Portfolio Pulse from Benzinga Newsdesk
September 28, 2023 | 2:14 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.